United States · Biotechnology startup
United States · Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company based in San Diego, California, founded in 2019.
Funding reportedLast round: Series C
About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company based in San Diego, California, founded in 2019.
The company is dedicated to developing innovative therapies for patients with life-threatening diseases, focusing primarily on fibrotic lung disease and oncology. Its mission is to create treatments that may slow disease progression and potentially reverse the trajectory of intractable conditions. Endeavor BioMedicines is advancing two lead investigational candidates: ENV-101, a small-molecule inhibitor targeting idiopathic pulmonary fibrosis, and ENV-501, an antibody-drug conjugate for HER3-positive solid tumors. The company has initiated clinical trials for both candidates, with promising early results for ENV-101 in improving lung function in patients with pulmonary fibrosis. Endeavor operates within the drug discovery and biotechnology sectors, emphasizing research and development aimed at addressing the underlying causes of terminal diseases.
What company datasets say Endeavor BioMedicines raised
Funding, as reported
Founders and team
From Endeavor BioMedicines's own website and the SEC filings it signed: 9 on the team.
- Anita DiFrancescoSenior Vice President, Clinical Operations
- Betsy GelfandSenior Vice President, Finance
- Hutch HumphreysVice President, Regulatory Affairs
- Randy AdamsSenior Vice President, Strategic Marketing & Communications
- Vishaal TurakhiaChief Financial Officer
- Chris KruegerExecutive Officeri
- Enoch KariukiExecutive Officeri
- John HoodExecutive Officer, Directori
- Miguel de los RiosExecutive Officeri
On the board, as filediBernard DavitianKaran Cheong TakharMonal Cheong MehtaPatrick G. EnrightWing Cheong Lam
On a portfolio page
Investors who name them
Each firm lists Endeavor BioMedicines on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
health careidiopathic pulmonary fibrosistransformational medicinesdisease trajectory reversalfibrotic disease therapymedical researchoncology drugsphase 2a clinical trialpost hoc analysistargeted therapybiotech leadershipfibrosis reversalclinical researchhospital & health careenv-101medical
Built with from their website
Google Tag ManagerWordPress.orgFont AwesomeYouTubeMax Mega MenuViewport MetaCookieYesBabelOWL CarouselPriority Hints
+8 more
Google Font APIimagesLoadedMicrosoft ExchangeMySQLPrimeNGwpBakeryMicrosoft 365 Apps & ServicesMobile Friendly
- Sector
- Biotechnology
- Industry code
- NAICS 541714, SIC 2834, 8731
- Region
- California
- Revenue
- $5.0M a year, as listed
- Full record
- Every detail in the company directory
Biotechnology in United States
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Endeavor BioMedicines in front of investors. Or tell us what we have wrong.